BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Aptuit Consulting, Inc. and Taiwan Liposome Company Collaborate to Complete all IND Enabling Work and IND Submission for Novel Anti-Cancer Treatment in 12 Months


6/25/2008 10:32:51 AM

TAIPEI, Taiwan & GREENWICH, Conn.--(BUSINESS WIRE)--Taiwan Liposome Company (TLC) and Aptuit Consulting Inc., a subsidiary of Aptuit Inc., today announced that TLC’s Lipotecan® cleared review by the U.S. Food and Drug Administration (FDA) following the filing of an Investigational New Drug (IND) application, the first anti-cancer drug from Taiwan to achieve this milestone. TLC will initiate a Phase 1 trial in patients with solid tumors in 3Q08. Lipotecan® is a chemically modified camptothecin designed to improve stability and potency and to minimize toxicity. Unlike other camptothecin-derived drugs that are used solely for chemotherapy, Lipotecan® has demonstrated effects as a chemotherapeutic and radio-sensitizer in preclinical animal studies. Aptuit Consulting, Aptuit’s global pharmaceutical drug development consultancy, managed the IND-enabling studies from manufacturing through IND submission and is engaged in the Phase 1 program.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES